Peroxisome proliferator activated dual receptor agonists

HP-jS-CD were added. All compounds were resolved in 20 min (see Figure 5). The data indicated that the validated method offered equivalent and complementary information, in terms of selectivity, sensitivity, accuracy, linearity, and precision, to that of an established gradient LC method employed for similar purposes. Ragaglitazar is a dual peroxisome proliferator-activated receptor ot and y agonist intended to restore insulin sensitivity and correct diabetic dyslipidemia. A chiral CZE method combining two CDs, sulfobutylether-jS-CD and dimethyl-/i-CD, lent itself to the analysis of ragaglitazar, its distomer (the (+)... 

Henke, B. R. Peroxisome proliferator-activated receptor alpha/ gamma dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 47(17), 4118-4127. 

Kasuga, J., Yamasaki, D., Araya, Y, Nakagawa, A., Makishima, M., Doi, T., Hashimoto, Y, Miyachi, H. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/ delta dual agonists for the treatment of metabolic syndrome. Bioorg. Med. Chem. 2006, 14, 8405-8414. 

A peroxisome proliferator-activated receptor a/y dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Molecular Endocrinology, 19, 1593-1605. 

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl] methyljglycine [muraglitazar/BMS-298585], a movel peroxisome proliferator-activated receptor a/y dual agonist with efficacious glucose and lipid-lowering activities. Journal of Medicinal Chemistry, 48, 2248-2250. 

Etgen, G.J., Oldham, B.A., Johnson, W.T. et al. (2002) A tailored therapy for the metabolic syndrome the dual peroxisome proliferator-activate receptor-a/y agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in predinical models. Diabetes, 51, 1083-1087. 

Henry RR, Lincoff M, Mudaliar S, Rabbia M, Chagnot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-ot/y agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY) a phase II, randomised, dose-ranging study. Lancet 2009 374 126-35. 

Peroxisome proliferator-activated receptors, see also Thiazohdinediones dual agonists, 32.782 Pertussis vaccine, 11.284,11.285 Phentermine, cardiac valvulopathies, 24.4 Pholcodine, 32.206... 

PEROXISOME PROLIFERATOR-ACTIVATED DUAL RECEPTOR AGONISTS... 

---